MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ
13.67
-0.45
-3.19%
After Hours: 13.67 0 0.00% 17:20 03/27 EDT
OPEN
13.75
PREV CLOSE
14.12
HIGH
14.13
LOW
13.34
VOLUME
1.20M
TURNOVER
--
52 WEEK HIGH
36.26
52 WEEK LOW
2.860
MARKET CAP
1.19B
P/E (TTM)
-7.3215
1D
5D
1M
3M
1Y
5Y
1D
Olema Pharmaceuticals Initiated at Peer Perform by Wolfe Research
Dow Jones · 1d ago
Wolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating
Benzinga · 1d ago
Olema Oncology initiated with a Peer Perform at Wolfe Research
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Olema Pharmaceuticals (OLMA) and Medios AG (OtherMEDOF)
TipRanks · 2d ago
Weekly Report: what happened at OLMA last week (0316-0320)?
Weekly Report · 5d ago
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
The Motley Fool · 6d ago
LifeSci Capital Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
TipRanks · 03/21 14:57
Olema Pharmaceuticals Price Target Cut to $40.00/Share From $43.00 by Jefferies
Dow Jones · 03/19 19:53
More
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

Webull offers Olema Pharmaceuticals Inc stock information, including NASDAQ: OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.